Microbiotica

Gut microbiome
#ESMO #Gut microbiome #Microbiotica #Oncology #Phase I trial

Trial data presented at ESMO support cancer microbiome therapy

Microbiotica has presented clinical data with encouraging efficacy from its Phase Ib MELODY-1 trial of MB097, a precision microbiome therapeutic for patients with advanced melanoma.  The data were presented in a poster at the European Society for Medical Oncology (ESMO) Congress 2026.  The MELODY-1 trial… Read More

#Cancer Research #Editor's Choice #News #Trending News

Microbiome
#Financing #Microbiotica #Phase II trial #Ulcerative colitis (UC)

Microbiotica raises £36 million to advance into Phase II

Biopharma company Microbiotica has closed £36 million in Series C financing to support the advancement of its treatment for ulcerative colitis. The financing was led by British Business Bank, with participation from Tencent, IP Group, Cambridge Innovation Capital, Flerie Invest, and Seventure Partners. All existing Series B investors… Read More

#Business & Investment #News

The microbiome
#Gut microbiome #Microbiome #Microbiotica #Preclinical development #Ulcerative colitis (UC)

Preclinical data reveals mechanism behind microbiome therapy

Microbiotica has revealed new data on the mechanism of action of MB310, its product in development as a treatment for ulcerative colitis (UC).   The data were shared at the Keystone Symposia ‘Human Microbiome: Diversity, Selection and Adaptation’ held 18-21 February in Banff, Canada and at the European… Read More

#News